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Summary To quantify the risk of second primary cancers among patients with cutaneous malignant
melanoma, we studied 20 354 patients in the Swedish Cancer Register during 1958-88. A second primary
cancer was reported in 1605 patients, compared with an expected number of 1109.5 [standardised incidence
ratio (SIR) = 1.45, 95% confidence interval (CI) = 1.38-1.52]. The highest risk was found among patients
younger than 60 years. The greatest risk was seen during the first year after diagnosis (SIR = 1.91,
CI = 1.69-2.14), but even after long-term follow-up - 15 years or more - the risk was still significantly
elevated (SIR = 1.56, CI = 1.35-1.79). The strongest association was found for a second primary malignant
melanoma (men, SIR = 10.0, CI = 8.26- 12.00; women, SIR = 8.66, CI = 7.22-10.30) and non-melanoma skin
cancer (men, SIR = 3.58, CI = 2.85-4.44; women, SIR = 2.41, CI = 1.71-3.29). The risk of second cancers
associated with tissues of neuroectodermal origin was increased, especially tumours of the nervous system
(men, SIR = 1.73, CI = 1.10-2.60; women, SIR = 2.03, CI = 1.45-2.78). The SIR of second cancers involving
the immune system was also increased. An excess risk of endometrial cancer was seen (SIR = 1.41,
CI = 1.03-1.88), but no significant associations existed for cancers of the breast, ovary, testis or other
endocrine glands. Among tumours of the digestive tract, only colon cancer in men had a significantly increased
SIR (1.33, CI = 1.00- 1.74).
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Several studies report coexistent or subsequent primary
malignant tumours among patients with malignant mel-
anoma. However, the proportions of patients having a
second primary cancer vary widely from 1.5% up to 20%
and comparisons between the studies are difficult owing to
differences in the length of follow-up (Fraser et al., 1971;
Fletcher, 1973; Boland et al., 1976; Teppo et al., 1985;
Tucker et al., 1985a; Gutman et al., 1991; Schallreuter et al.,
1993). Previous studies suggest associations between malig-
nant melanoma and an array of different specific types of
cancer, such as tumours of the nervous system (Teppo et al.,
1985; Tucker et al., 1985a), non-melanoma skin cancer
(Fraser et al., 1971; Fletcher, 1973; Lindelof et al., 1991),
Hodgkin's disease (Tucker et al., 1985b), non-Hodgkin's lym-
phoma (Teppo et al., 1985), leukaemia (Boland et al., 1976;
Teppo et al., 1985), cancers of the breast (Boland et al., 1976;
Schoenberg and Christine, 1980; Gutman et al., 1991; Schall-
reuter et al., 1993), ovary (Boland et al., 1976), endometrium
(Tucker et al., 1985a), testis (Teppo et al., 1985) and tumours
of the digestive tract (Bergman et al., 1990). Taken together,
these earlier observations may fit into different hypotheses
based on similar risk factors in malignant melanoma and
other specific cancers. Causative factors in common may be
genetic factors predisposing for tumour development, envir-
onmental exposures such as UV light, impaired immuno-
logical mechanisms, gender-specific and hormonal factors or
other largely unknown risk factors.
Our aim was 2-fold: first, to quantify the short-term and
long-term risks of developing a second primary cancer
among patients with cutaneous malignant melanoma and,
secondly, to test the above-mentioned hypotheses. We used
the Swedish national cancer register, which has an almost
complete and long-term follow-up of the registered patients.
Materials and methods
Cancer register
Since 1958, all new cases of cancer in Sweden have been
reported to the Swedish Cancer Register (The Cancer
Register, 1960-91) at the National Board of Health and
Welfare. An almost 100% coverage in cancer registration
(Mattsson and Wallgren, 1984) has been achieved by compul-
sory reporting by clinicians who diagnose a malignant disease
and the pathologists/cytologists who must report separately
any diagnosis of cancer made on pathological and cytological
specimens. The site of the cancer is registered according to
the WHO classification (World Health Organization, 1957).
The stage of the disease or treatment is not recorded in the
Cancer Registry.
Patients
All patients with a first malignant melanoma diagnosed
between 1 January 1958 and 31 December 1988 were col-
lected from the Cancer Register, a total of 20354 cases. The
follow-up was completed by linkage of the cohort to the
Cause of Death Register (Statistics Sweden, 1959-91), to a
register covering emigration and a register of all living per-
sons in the population. The whole cohort was then followed
up to record incident cases of a second primary cancer.
Statistical methods
Person-years at risk were calculated from the date of diag-
nosis of malignant melanoma to the closing date of the
follow-up, which was either the date of death or the date of
diagnosis of a second primary cancer. Otherwise it was the
end of follow-up at 31 December 1988. To estimate the
expected number of cases of second primary cancers, we
multiplied the number of person-years by the Swedish age-
specific incidence rates for each calendar year separately for
these cancer sites.
The standardised incidence ratio (SIR) is defined as the
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ratio between the observed number of cases (with a new
second primary cancer) and the expected number of cases.
Thus, the SIR is a relative measure of the risk that a patient
with a diagnosis of malignant melanoma will develop a
second primary cancer. A 95% confidence interval was cal-
culated by assuming a Poisson distribution of the observed
number of cases.
Results
All sites
There were 20 354 patients with a diagnosis of malignant
melanoma, 9617 men and 10 737 women. The average age at
diagnosis was 56.7 years and the mean follow-up time was
6.5 years. A total of 132 289 person-years at risk was
counted and a subsequent second primary cancer was found
in 1605 patients (7.9%). 792 men and 813 women. The
expected number of cases was estimated to be 1109.5 and the
SIR was 1.45 (95% confidence interval (CI) = 1.38-1.52).
The overall SIR was also calculated separately for men
and women in all age groups and divided into two age
groups: below 60 years of age at diagnosis of primary malig-
nant melanoma and 60 years or above. Age 60 was chosen as
age cut-off since it was close to the average age at diagnosis
(56.7 years). In all the separate age groups, the SIR was
significantly elevated, the highest figure being found among
men less than 60 years of age who had a SIR of 1.85
(CI = 1.65-2.07), whereas women aged 60 years or older had
the lowest risk, SIR was 1.26 (CI = 1.14-1.38) (Table I).
SIR was calculated by years of follow-up for both sexes
combined. We found the highest risk of developing a second
primary cancer during the first year after diagnosis, the SIR
was 1.91 (CI = 1.69-2.14) and it decreased during the fol-
lowing 4 years after diagnosis to 1.29 (CI = 1.18-1.41). Dur-
ing prolonged follow-up (15 years or more), the SIR in-
creased to 1.56 (CI = 1.35-1.79) (Table II).
Special sites
Tissues of neuroectodermal origin The relative risk of
developing any tumour of the nervous system, eyes or endoc-
rine glands was elevated in patients with malignant
melanoma (Table III). The SIR of having a second primary
cancer in the nervous system was in men 1.73 (CI
= 1.10-2.60) and in women 2.03 (CI = 1.45-2.78). Analysis
of SIR by age at diagnosis ofmalignant melanoma and years
of follow-up showed that the increased risk of second
primary tumours of the nervous system was confined to the
first 4 completed years of follow-up in men 60 years or older
and in women irrespective of age (data not shown). Two
observed eye cancers were malignant melanomas, the third
one was not histopathologically classified. The group of
endocrine gland tumours consisted of adrenal gland,
parathyroid gland, thymes, pituitary, insuloma of pancreas,
other endocrine glands, multiple endocrine glands, uns-
pecified endocrine glands. In this group of endocrine gland
tumours, 33% of the observed cases consisted of tumours
derived from the neuroectoderm. It was not possible to cal-
culate the proportion of neuroectodermally derived endocrine
gland tumours among the expected cases.
Skin The SIR of a second primary malignant melanoma
was substantially elevated to 10.00 (CI = 8.26-12.00) among
men and to 8.66 (CI = 7.22-10.30) among women (Table
III). The risk of second primary malignant melanoma was
increased in all ages and during both short- and long-term
follow-up (data not shown). There was also an increased risk,
SIR around 3-fold, for developing squamous cell and basal
cell carcinoma (type mixed).
Haematopoietic and lymphoproliferative tissues Patients with
malignant melanoma ran an increased risk of second primary
cancers developing in the 'immune system', the SIR being
1.29 (CI = 1.05-1.57). Elevated risks were found for non-
Hodgkin's lymphoma, Hodgkin's disease, lymphatic leuk-
aemia (men), myeloid leukaemia, multiple myeloma (men)
and 'other' leukaemias (Table III). However, except myeloid
leukaemia in women and 'other' leukaemias in men, none of
these separate relationships was significant. 'Other' leuk-
aemias were acute leukaemia (Blastcell leukaemia), which
was diagnosed 1 year and 7 months after the diagnosis of
primary malignant melanoma, stemcell leukaemia (1 year, 8
months) and myelomonocytic leukaemia (4 months).
Sex-specific or hormone-related tissues No excessive risks of
developing breast or ovarian cancer were found among
women with a prior diagnosis of malignant melanoma. How-
ever, the SIR for cancer of the endometrium was increased
significantly to 1.41 (CI= 1.03-1.88) (Table IV). Analysis by
years of follow-up and age at diagnosis of malignant
melanoma indicated that the risk of endometrial cancer was
elevated during both short- and long-term follow-up mainly
in women younger than 60 years of age (data not shown).
High SIRs, although not significant, were found for tumours
of the endocrine glands in both men and women, 1.78
(CI = 0.81-3.37) and 1.34 (CI = 0.79-2.12) respectively.
Only one case of testis carcinoma occurred in men with
malignant melanoma.
Digestive tissues The only significant increase in SIR was
found for colon cancer in men: SIR 1.33 (CI = 1.00-1.74)
(Table IV). SIRs that were slightly increased, but not
significant, were found for oesophagus cancer in men and
rectum cancer in women, 1.37 (CI = 0.66-2.52) and 1.21
(CI = 0.82-1.72) respectively. There were fewer observed
cases than expected cases of stomach cancer in men. A
similar, though weaker, association was detected for cancer
of the pancreas in both men and women. Regarding tumours
TableII SIR ofdeveloping a second primary cancer in patients with a
diagnosis of malignant melanoma recorded in the Swedish Cancer
Register, 1958-88, by years of follow-up.
Completedyears offollow-up 0 E SIR (95% CI)
<1 year 286 150.0 1.91 (1.69-2.14)
1-4 years 514 398.8 1.29 (1.18-1.41)
5-9 years 389 280.3 1.42 (1.28-1.57)
10-14 years 210 154.0 1.36 (1.19-1.56)
> 15 years 197 126.3 1.56 (1.35-1.79)
0, observed number of cases; E, expected number of cases.
Table I SIR of developing a second primary cancer in patients with a diagnosis of
malignantmelanoma recorded intheSwedish CancerRegister, 1958-88,bysexand ageat
diagnosis.
Age at Men Women
diagnosis 0 E SIR (95% CI) 0 E SIR (95% CI)
All ages 792 521.1 1.52 (1.42-1.63) 813 588.4 1.38 (1.29-1.48)
<60 years 313 168.8 1.85 (1.65-2.07) 392 253.5 1.55 (1.40-1.71)
> 60 years 479 352.3 1.36 (1.24-1.49) 421 334.9 1.26 (1.14-1.38)
0, observed number of cases; E, expected number of cases.of the mouth and the hypopharynx, the numbers of observed
and expected cases were small in both sexes. In general,
patients with malignant melanoma do not run an increased
risk of developing a second primary cancer in sites of the
digestive system.
Discussion
The present study was population-based and included all
20 354 incident cases of cutaneous malignant melanoma
recorded in the Swedish Cancer Register from 1958 to 1988.
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The largest previous study was based on 3984 cases (Teppo
et al., 1985). Our large number of cases allowed us to create
cohorts of sufficient sizes with long-term and complete
follow-up through computerised linkage of registers. There
are sex-specific differences in incidence and survival from
malignant melanoma in Sweden (Thorn et al., 1987, 1990).
Consequently, the risk of second primary tumours may differ
by gender and we think it is important to present most of the
results for men and women separately.
Overall underreporting to the Swedish Cancer Register was
estimated at 4.5% and less than 2% for histologically
confirmed cases (Mattsson and Wallgren, 1984). In our
Table III SIR ofdeveloping a second primary cancer in tissues ofneuroectodermal origin, skin, haematopoietic and
lymphoproliferative tissues in patients with a diagnosis of malignant melanoma recorded in the Swedish Cancer
Register, 1958-88, by sex and specified site.
Site ofnew cancer
Neuroectodermal tissues
Nervous system
Eye
Endocrine glands
All neuroectodermal
tumoursa
Skin
Cutaneous malignant
melanoma
Non-melanoma
Skin cancerb
All skin tumoursa
Haematopoietic and lympho-
proliferative tissues
Non-Hodgkin's
lymphoma
Hodgkin's disease
Lymphatic leukaemia
Myeloid leukaemia
Multiple myeloma
Other leukaemia
All haematopoietic and
lympho-proliferative
tumoursa
Men
0 E SIR (95% CI)
23
9
32
13.2
1.3
5.1
19.6
1.73 (1.10-2.60)
- (0.00-2.84)
1.78 (0.81-3.37)
1.63 (1.12-2.30)
116 11.6 10.00 (8.26-12.00)
83 23.2 3.58 (2.85-4.44)
199 34.8 5.72 (4.95-6.57)
20 14.5 1.37 (0.84-2.12)
5
11
5
9
3
53
2.8
9.2
4.4
8.5
0.2
39.6
1.79 (0.58-4.19)
1.19 (0.60-2.13)
1.12 (0.36-2.62)
1.06 (0.49-2.02)
18.58 (3.83-54.30)
1.34 (1.00-1.75)
Women
0 E SIR (95% CI)
39 19.2 2.03 (1.45- 2.78)
3 1.4 2.22 (0.46- 6.47)
18 13.4 1.34(0.79- 2.12)
60 34.0 1.76(1.35- 2.27)
127 14.7 8.66 (7.22-10.30)
39 16.2 2.41 (1.71- 2.39)
166 30.9 5.37 (4.59- 6.25)
18 14.2 1.26 (0.75-2.00)
4
6
10
8
46
2.7
7.2
4.8
8.4
0.1
37.4
1.50 (0.41-3.85)
0.83 (0.31-1.81)
2.09 (1.00-3.85)
0.95 (0.41-1.88)
- (0.00-36.89)
1.23 (0.90- 1.64)
aWhenSIRwascalculatedforall tumoursinthegroup, thenumbersofobservedcasesandexpectedcaseswereadded
separately together. This calculation introduces a small error due to differences in person-years which, however, was
negligible anddid notchange theresults. b Non-melanoma skincancerconsisted ofsquamouscellcarcinomaand basal
cell carcinoma type mixed. 0, observed number of cases; E, expected number of cases.
Table IV SIR of developing a second primary cancer in sex-specific or hormone-related tissues and
digestive tissues in patients with a diagnosis of malignant melanoma recorded in the Swedish Cancer
Register, 1958-88, by sex and specified site.
Men Women
Site ofnew cancer 0 E SIR (95% CI) 0 E SIR (95% CI)
Sex-specific or hormone-
related tissues
Breast 151 147.5 1.02 (0.87-1.20)
Ovary 37 34.8 1.06 (0.75-1.46)
Endometrium 46 32.7 1.41 (1.03-1.88)
Testis 1 1.8 0.56 (0.01-3.12)
Endocrine glands 9 5.1 1.78 (0.81-3.37) 18 13.4 1.34 (0.79-2.12)
All tumoursa 10 6.9 1.45 (0.69-2.67) 252 228.4 1.10 (0.97-1.25)
Digestive tissues
Floor of the mouth 1 0.9 1.16 (0.03-6.44) - 0.3 - (0.00-12.28)
Hypopharynx 1 1.6 0.62 (0.02-3.47) 1 0.6 1.59 (0.04-8.88)
Oesophagus 10 7.3 1.37 (0.66-2.52) 2 3.3 0.60 (0.07-2.18)
Stomach 28 37.1 0.76 (0.50-1.09) 27 28.2 0.95 (0.63-1.39)
Small intestine 5 3.0 1.65 (0.54-3.86) 2 2.9 0.69 (0.08-2.48)
Colon 54 40.6 1.33 (1.00-1.74) 53 53.2 1.00 (0.75-1.30)
Rectum 29 27.7 1.04 (0.70-1.50) 31 25.6 1.21 (0.82-1.72)
Biliary passages 14 15.7 0.89 (0.49-1.49) 24 24.4 0.98 (0.63-1.46)
and liver
Pancreas 17 20.3 0.84 (0.49-1.34) 18 22.2 0.81 (0.48-1.28)
All tumours in 159 154.2 1.03 (0.88-1.20) 158 160.7 0.98 (0.84-1.15)
digestive tissuesa
a When SIRwascalculated forall tumours inthegroup, thenumbersofobserved casesandexpectedcases
were added separately together. Thiscalculation introduces asmall errordue to differences in person-years
which, however, was negligible and did not change the results. 0, observed number ofcases; E, expected
number of cases.Pip_ Second primary cancer in melanoma
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study, underreporting had the same effect on both the
observed and the expected number of cases and since the SIR
is the quotient between them the result will not be changed.
The fact that patients with melanoma have already developed
one type of cancer may lead to frequent medical follow-ups
and early detection of second cancers. The finding of a high
risk during the first year after diagnosis may have resulted
from increased surveillance. However, since the risk of
second primary cancer was also high after long-term follow-
up, surveillance bias cannot be the main explanation of our
results. Finally, we cannot exclude the possibility that a
single metastasis was registered as a new primary cancer. In
suspected cases, we checked the histopathological reports in
the Cancer Register. Misclassification was rare - for instance
among 52 random cases of a second primary malignant
melanoma we found only one metastasis misclassified as a
new primary tumour. In summary, we believe it is unlikely
that our results have been seriously distorted by the potential
sources of bias mentioned above.
Our nationwide study showed that patients with malignant
melanoma in Sweden run a 45% higher risk of developing
second primary cancers than does the general population.
The risk was most marked within the first year after diag-
nosis (SIR = 1.91, CI = 1.69-2.14) and was somewhat lower
1-4 years after diagnosis (SIR= 1.29, CI= 1.18-1.41), but
even after long-term follow-up, 15 years or more, the risk of
a second primary cancer was significantly increased (SIR
= 1.56, 1.35-1.79). The highest risk was found among
patients who had their malignant melanoma diagnosed
before the age of 60. If a second primary malignant
melanoma and a second non-melanoma skin cancer were
omitted, the SIR was reduced to 1.16 (CI = 1.10- 1.23).
However, a similar pattern according to age, sex and follow-
up time emerged. The increased risk of a second primary
cancer among melanoma patients may have several explana-
tions. There may be a common genetic abnormality predis-
posing to tumours developing in the same patient. Recently,
mutations of a newly discovered tumour-suppressor gene
coding for cell-cycle regulating protein called p16 have been
described in a majority of malignant melanomas and also in
other tumours (Kamb et al., 1994; Nobori et al., 1994).
Another conceivable explanation is an increased susceptibility
to cancer in general due either to increased exposure to
carcinogens or to an impairment of immunological defence
mechanisms against malignant tumours. It is also possible
that treatment of metastatic melanoma with cytotoxic agents
or radiotherapy depresses the host defence and facilitates the
initiation and promotion of second primary tumours.
We found an increased SIR for tissues of neuroectodermal
origin that was most marked for tumours of the nervous
system. The histopathological coding showed that all these
tumours were new primary tumours and no misclassification
with inclusion of metastases from malignant melanoma was
detected. Significantly increased risks of developing tumours
of the nervous system in association with malignant
melanoma have been described in both directions (Teppo et
al., 1985; Tucker et al., 1985a). These findings lend support
to the hypothesis that underlying causative factors affect
tissues derived from the neuroectoderm. Some of these
tumour sites are similar to those associated with
neurofibromatosis, however in the present study it was not
possible to find out if any of the patients had this disease.
Further studies are needed to confirm similarities in car-
cinogenesis among neuroectodermal tissues.
In the present study, the risk of developing new skin
malignancies was markedly increased. The highest SIR was
found for second primary malignant melanomas (SIR
= 9.24). Simarly, Tucker and collaborators found in patients
with melanoma a relative risk of 8.5 to develop a second
primary malignant melanoma (Tucker et al., 1985a). Sun
exposure, especially during childhood, resulting in painful
sunburn is an important risk factor for malignant melanoma
(Magnus, 1977; Lee, 1982; Evans et al., 1988; Osterlind et al.,
1988). It is not known whether second primary malignant
melanomas are caused by additional sun exposure among
melanoma patients or if these tumours develop as a result of
earlier exposure. Reasonably, malignant melanoma patients
should avoid excessive sun exposure because of the risk of
developing second primary malignancies of the skin.
According to our results, malignant melanoma patients run
a somewhat increased risk of cancers associated with the
immune system. Immunological abnormalities have been
reported in families that are genetically predisposed to
developing malignant melanoma (Hersey et al., 1979). An
increased risk of malignant melanoma has been documented
in patients receiving immunosuppressive treatment, such as
renal transplant recipients (Greene et al., 1981) and also in
patients with chronic lymphocytic leukaemia (Greene et al.,
1978; Travis et al., 1992), Hodgkin's disease (Tucker et al.,
1985b; van Leeuwen et al., 1994) and non-Hodgkin's lym-
phoma (Travis et al., 1991, 1993). Thus, patients with
immune dysfunction seem to run an increased risk of
developing malignant melanoma. On the other hand, malig-
nant melanoma may also predispose to tumours developing
in the immune system.
The present study showed among women an increase in
the risk of a second primary cancer of the endometrium but
no increase in the risk of cancer of the breast or ovary. In
animal experiments, oestrogens stimulate melanogenesis and
increase the number of melanocytes (Snell and Bischitz,
1960). Oestrogen receptors and progesterone receptors have
been identified in human malignant melanoma cells (Fisher,
1976; Stedman et al., 1980). In addition, the reported pro-
gression of malignant melanoma during pregnancy and spon-
taneous regression after parturition favour a hormonal effect
on melanoma cells (Slingluff et al., 1990). A possible role of
oestrogens may be supported by the elevated SIR we found
for second primary cancers of the endometrium and colon,
which both exhibit oestrogen receptors (Stedman et al.,
1980). However, this explanation is partly refuted by our
finding of an unchanged risk of breast cancer and ovarial
cancer after diagnosis of primary malignant melanoma.
The dysplastic naevus syndrome or the FAMMM synd-
rome is characterised by the familial occurrence of cutaneous
malignant melanoma and dysplastic naevi. Earlier results
indicate that some members of a family with this syndrome
run an increased risk of developing systemic cancer,
especially cancer of the digestive tract (Bergman et al., 1990).
On this basis, we investigated whether malignant melanoma
patients run a greater risk of developing cancer of the diges-
tive tract. Apart from an increased risk of colon cancer
among men with malignant melanoma, no relationships were
found between malignant melanoma and an increased risk of
second primary cancers in the digestive tract.
In conclusion, our study shows that patients with a first
diagnosis ofmalignant melanoma in general run an increased
risk of developing a second primary cancer. In particular,
young melanoma patients have a greater risk of additional
cancers later in life. Follow-up programmes with a close
medical surveillance should be considered in patients with
malignant melanoma, since these can lead to earlier diagnosis
of second primary cancers. A markedly elevated risk was
found for the development of another malignant melanoma
or non-melanoma skin cancer, and to avoid a further risk of
second primary cancers of the skin, malignant melanoma
patients should be careful with sun exposure after their first
diagnosis. Further, we detected an increased risk of neuroec-
todermal tumours, which at least partly supports the
hypothesis of an underlying genetic abnormality in subgroups
of patients with cutaneous malignant melanoma.
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